Shareholders' Equity - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended				3 Months Ended				9 Months Ended		21 Months Ended	24 Months Ended
	Apr. 22, 2024	Jan. 07, 2024	Jun. 30, 2025	Jan. 31, 2025	Dec. 31, 2024	May 31, 2024	Sep. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2025	Aug. 31, 2024	May 01, 2024	Oct. 31, 2023
Purchase Agreement, Knopp Amendment
Nature of business [Line Items]
Number of securities called by warrants (shares)																294,195
Exercise price of warrants (in dollars per share)																$ 67.98
Warrants, fair value disclosure																$ 3,340
Common Shares
Nature of business [Line Items]
Common stock issued (shares)									2,154,857	8,544,951
Issuance of common shares, net of offering costs									$ 76,361	$ 317,720
Obligation to issue common shares as payment under license and other agreements (in shares)								222,119
Obligation to issue common shares as payment under license and other agreements								$ 8,554
Number of shares sold in transaction (in shares)	6,451,220
Issuance price per share (in dollars per share)	$ 41.00
Proceeds from sale of stock	$ 247,830
Equity distribution agreement aggregate amount							$ 300,000				$ 300,000		$ 300,000	$ 300,000	$ 450,000		$ 150,000
Common Shares | Equity Distribution Agreement
Nature of business [Line Items]
Common stock issued (shares)														4,248,588
Proceeds from sale of stock														$ 146,250
Pyramid Biosciences, Inc.
Nature of business [Line Items]
Upfront payment of common shares, shares (in shares)		255,794,000
Upfront payment of common shares, value		$ 10,894
Upfront payment of common shares, shares issued (in shares)													253,838,000
Research and development							$ 0		$ 0		$ 0	$ 5,689
Common shares issuable (in shares)												98,129
Common shares issued (in shares)											97,387
Purchase Agreement, Knopp Amendment
Nature of business [Line Items]
Common stock issued (shares)			3,588,688			1,872,874
Issuance of common shares, net of offering costs			$ 51,426			$ 65,981
Merus N.V. Agreement
Nature of business [Line Items]
Common stock issued (shares)				132,700
Issuance of common shares, net of offering costs				$ 4,844
FGFR3 Agreement, GeneQuantum Healthcare (Suzhou) Co. Ltd. and Aimed Bio, Inc.
Nature of business [Line Items]
Obligation to issue common shares as payment under license and other agreements (in shares)					222,119
Obligation to issue common shares as payment under license and other agreements					$ 8,554